HUTCHMED (China) Ltd

Approval AI-extracted

sovleplenib

warm antibody autoimmune hemolytic anemia

Date

TBD

Approval decision · Date TBD estimated

What's at stake A final FDA approval decision on sovleplenib for warm antibody autoimmune hemolytic anemia is expected Date TBD.

Primary source · SEC 6-K verified 12h ago

“The NMPA accepted for review the resubmitted NDA filing for the treatment of ITP and granted it priority review in February 2026.”